Researchers at The University of Texas MD Anderson Cancer Center have identified a six-gene signature in microscopic colorectal cancer (CRC) liver metastases that may predict recurrence risk and chemotherapy resistance. According to a study published in Cancer Cell, these tiny, often undetectable tumor deposits serve as a tissue-based marker for residual cancer cells that persist after treatment.
Understanding the Six-Gene Signature for Colorectal Cancer Recurrence
Colorectal cancer recurrence is often driven by minimal residual disease (MRD)—small clusters of cancer cells that survive initial surgery or chemotherapy. While blood-based circulating tumor DNA (ctDNA) tests can identify the presence of these cells, they often fail to locate them or explain their survival mechanisms. The new research, co-led by Dipen Maru, M.D., and Linghua Wang, M.D., Ph.D., utilized high-resolution spatial profiling to analyze 49 tumors from 19 patients, comparing gene activity in micrometastases against larger tumors and healthy tissue.
The team isolated a specific six-gene signature, dubbed “MicroMetSig-high.” Patients exhibiting higher levels of this signature demonstrated shorter disease-free survival times and a higher likelihood of treatment resistance. By identifying these dormant, stem-like cell clusters, clinicians may eventually be able to distinguish between patients who require standard follow-up and those who need more aggressive, personalized interventions.
Pro Tip: Currently, ctDNA is the standard for detecting MRD. This research suggests that in the future, combining blood-based markers with tissue-based genetic signatures could provide a more comprehensive map of a patient’s metastatic risk.
How Hidden Micrometastases Evade the Immune System
A major hurdle in cancer treatment is the ability of residual cells to hide from the immune system. The MD Anderson study found that liver micrometastases are not merely smaller versions of larger tumors; they occupy a distinct biological state. Spatial mapping revealed that these microscopic clusters are frequently surrounded by immune cells, but those cells are often “exhausted” and lack the ability to effectively attack the cancer.
The micrometastases displayed immune-suppressing signals, specifically through pathways such as PD-1/PD-L1. According to the study authors, these pathways represent potential future therapeutic targets. If clinicians can “reawaken” the immune system’s ability to recognize these hidden cells, it may be possible to clear residual disease before it manifests as a clinical relapse.
Future Directions for Metastatic Cancer Research
While the six-gene signature shows promise, the research team emphasizes that it is not yet a clinical test. Larger cohorts are required to validate these findings and establish clinical efficacy. Future studies will focus on functional analysis to determine exactly how these dormant cells survive chemotherapy and suppress the surrounding immune environment.
“Micrometastases are not simply smaller versions of macrometastases, but rather they appear to represent a distinct biological state,” said Dr. Wang. The goal of this ongoing research is to bridge the gap between liquid biopsies and the physical location of residual disease, moving toward a more precise, individualized approach to oncology.
Frequently Asked Questions
What is minimal residual disease (MRD)?
MRD refers to the presence of small numbers of cancer cells that remain in the body after a patient has undergone surgery or chemotherapy. These cells are often invisible to routine imaging scans.
Why do some patients relapse even after visible tumors are removed?
Relapse often occurs because microscopic clusters of cells, known as micrometastases, survive initial treatment. These cells can remain dormant for a period before growing into new, detectable tumors.
Could this six-gene signature replace current tests?
No. Researchers suggest that this signature is intended to complement existing blood-based tests rather than replace them, providing a more detailed look at the biology driving the cancer’s persistence.
Is this test available for patients now?
Not yet. The researchers note that while the findings are encouraging, larger studies are necessary before this gene signature can be developed and validated for use in clinical settings.
Are you interested in the latest breakthroughs in oncology and personalized medicine? Subscribe to our newsletter for updates on clinical research and emerging treatment strategies. If you have questions about your own treatment plan, please consult your oncology care team at an NCI-designated cancer center.
Keep reading
